Meeting
2015 ASCO Annual Meeting
First-in-man combination phase I study of TAS-114 and S-1 in patients (pts) with advanced solid tumors.
Authors
Toshihiko Doi
National Cancer Center Hospital East, Chiba, Japan
Toshihiko Doi , Kiyotaka Yoh , Kohei Shitara , Hideaki Takahashi , Makoto Ueno , Satoshi Kobayashi , Manabu Morimoto , Shinichi Ohkawa , Takuji Okusaka , Hideki Ueno , Chigusa Morizane , Satoshi Shiba , Naohiro Okano , Daisuke Naruge , Fumio Nagashima , Junji Furuse , Kazuo Koba , Kazuharu Noguchi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Cytotoxic and Other Novel Agents
Clinical Trial Registration Number
NCT01610479
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2544)
DOI
10.1200/jco.2015.33.15_suppl.2544
Abstract #
2544
Poster Bd #
260
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.
First Author: Jing Huang
Poster
2018 ASCO Annual Meeting
Phase Ib trial of nivolumab combined with metformin for refractory/recurrent solid tumors.
First Author: Toshio Kubo
Poster
2017 ASCO Annual Meeting
Phase I study combining MLN8237 with nab-paclitaxel in patients with advanced solid malignancies.
First Author: Kian-Huat Lim
Poster
2013 ASCO Annual Meeting
A phase I dose-escalation study of volasertib (BI 6727) combined with nintedanib (BIBF 1120) in advanced solid tumors.
First Author: Filippo G. De Braud